Lacarya Scott
Founding Partner

As Founding Partner of Tungsten, Lacarya brings experience from academia, hedge funds, and corporate development.
Lacarya started his career at Life Technologies (formerly Invitrogen Corporation) as an associate in the M&A group, working on all aspects of M&A deals totaling $1.5 Billion from target selection, financial analysis and valuation, to presenting transactions to the Board for final deal approval.
After Life Technologies, Lacarya worked at Caxton Associates, a $15 Billion global macro and sectorial hedge fund, investing in many public and private biotechnology companies, serving on the Boards of several companies, and arranging exits via strategic sales. One notable exit was the sale of GeminX to Cephalon for $525 Million which transaction generated a 4x return over a 3-year holding period.
After Caxton, Lacarya worked at Jermyn Street Capital and Ferghana Partners and served as VP Business Development and Corporate Strategy at several other private and public life science companies such as Mesoblast.
During Lacarya’s academic training at NYU, Lacarya completed his research on (1) serotonin and its role in cell death and suicide; (2) PPAR-γ and its role in atherosclerosis via macrophage cells.

EDUCATION + CERTIFICATION

AB in Biophysics from Princeton University.
MS in Biology and a research focus in Biological Chemistry from New York University.
MS in Engineering Biotechnology from University of Pennsylvania.
MBA in Finance from The Wharton School, University of Pennsylvania.
Mr. Scott holds the CFA designation.
Mr. Scott holds FINRA licenses: Securities Industry Essentials, Series 63 and Series 79.
Mr. Scott is Registered Representative of Finalis Securities LLC Member FINRA/SIPC.

Lacarya ScottFounding Partner